FEMY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $2.05
Market Cap (MRQ) $6M
P/E (TTM) -1.5
EPS (TTM) $-1.41
Revenue (TTM) $2M
ROE (TTM) -425.0%
52W Range $0–$8

FEMY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1
Ex-date Split Type
June 8, 2026 1-for-20 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$2M
2020-12-31 → 2025-12-31
EPS$-0.47
2020-12-31 → 2025-12-31
Free Cash Flow$-19M
2021-12-31 → 2025-12-31
Net margin-511.8%
2021-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend FEMY 5Y avg Peer Median Verdict
P/E (TTM) -1.55Y avg ≈-1.6 ≈-1.6 · ·
P/S (TTM) 2.75Y avg ≈19.7 ≈19.7 5.5 Fair value
P/B (MRQ) 1.55Y avg ≈4.9 ≈4.9 2.4 Overvalued
Price / FCF (TTM) -0.35Y avg ≈-2.4 ≈-2.4 · ·
Price / Cash Flow (TTM) -0.45Y avg ≈-2.5 ≈-2.5 · ·
Price / Tangible Book (MRQ) 1.65Y avg ≈4.2 ≈4.2 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 15.6%
Next Report Nov 12, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 14, 2026 $-1.55 $-1.33 -16.9%
March 31, 2026 May 7, 2026 $-1.20 $-1.84 34.6%
Dec. 31, 2025 $-0.20 $-1.78 88.8%
Sept. 30, 2025 $-2.00 $-2.65 24.6%
June 30, 2025 $-3.00 $-3.67 18.3%
March 31, 2025 $-0.23 $-0.19 -18.7%
Dec. 31, 2024 $-0.23 $-0.19 -21.9%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 18
Metric Trend 202520242023202220212020
Revenue $2M$2M$1M$1M$1M$1M
Cost of Revenue $872.4K$544.9K$380.1K$441.9K$370.4K$306.5K
Gross Profit ···$764.3K$809.3K$731.4K
R&D Expense $8M$8M$7M$6M$4M$4M
SG&A Expense $7M$6M$7M$5M$4M$3M
Operating Expenses $19M$19M$15M$12M$9M$8M
Operating Income $-18M$-18M$-15M$-12M$-8M$-7M
Interest Expense ··$165.4K$13.5K$19.2K$12.6K
Interest Income $101.8K$582.4K$431.0K···
Other Non-op $-482.6K$0$265.6K$212.4K$803.0K$20.0K
Pretax Income $-19M$-19M$-14M$-11M$-8M$-7M
Income Tax $1.3K$9.6K$4.3K$6.3K$4.0K$1.8K
Net Income $-19M$-19M$-14M$-11M$-8M$-7M
EPS (Basic) $-0.47$-0.85$-0.93$-0.96$-1.12$-7.20
EPS (Diluted) $-0.47$-0.85$-0.93$-0.96$-1.12$-7.20
Shares (Basic) 39,549,21822,267,69515,384,37611,815,0196,712,028959,862
Shares (Diluted) 39,549,21822,267,69515,384,37611,815,0196,712,028959,862
EBITDA $-18M$-18M·$-12M$-8M·
Balance Sheet 27
Metric Trend 202520242023202220212020
Cash & Equivalents $9M$3M$22M$13M$25M$3M
Receivables $616.6K$488.4K$98.9K$77.5K$84.3K$125.8K
Inventory $6M$3M$667.1K$436.7K$208.3K$131.4K
Other Current Assets $833.1K$1M$695.9K$655.4K$555.9K$284.1K
Current Assets $16M$8M$23M$14M$26M$4M
PP&E (Net) $2M$2M$1M$1M$2M$2M
PP&E (Gross) $6M$5M$5M$5M$4M$4M
Accum. Depreciation $4M$4M$4M$3M$3M$2M
Intangibles $134.9K$65.9K$0$3.3K$25.1K$65.1K
Other Non-current Assets $940.2K$955.0K$1M$958.2K$655.4K$792.4K
Total Assets $21M$12M$28M$17M$29M$8M
Accounts Payable $2M$1M$1M$510.8K$445.5K$674.3K
Accrued Liabilities $1M$1M$1M$456.7K$603.8K$1M
Short-term Debt ·$0$0$141.3K$181.1K$630.0K
Current Liabilities $4M$9M$3M$2M$2M$3M
Capital Leases $1M$2M$2M$28.6K$386.2K$769.8K
Other Non-current Liabilities ····$0$32.9K
Total Liabilities $15M$10M$9M$2M$2M$4M
Total Debt ···$141.3K$181.1K·
Common Stock $3.0K$23.5K$21.8K$12.0K$11.9K$1.1K
Paid-in Capital $147M$128M$124M$109M$108M$23M
Retained Earnings $-146M$-127M$-108M$-94M$-83M$-75M
Treasury Stock $60.0K$60.0K$60.0K$60.0K$60.0K$60.0K
AOCI ····$0$0
Stockholders' Equity $6M$2M$18M$15M$26M$-52M
Liabilities + Equity $21M$12M$28M$17M$29M$8M
Shares Outstanding 2,980,25423,355,92621,657,38111,869,70411,804,165993,124
Cash Flow 14
Metric Trend 202520242023202220212020
D&A $342.0K$297.3K$483.5K$561.2K$591.1K$679.7K
Stock-based Comp $790.1K$444.1K$675.7K$224.9K$193.4K$318.6K
Deferred Tax $-4M$0$0$0$-2M·
Amort. of Intangibles $46.2K$20.1K$3.3K$21.8K$40.0K$118.9K
Operating Cash Flow $-19M$-19M$-11M$-11M$-8M$-5M
CapEx $525.0K$761.7K$143.9K$407.5K$306.9K$8.4K
Investing Cash Flow $-630.1K$-847.8K$-143.9K$-407.5K$-306.9K$968.3K
Stock Issued ·$2M$8M$59.6K$32M$153.2K
Stock Repurchased ·$60.8K$230.0K$0··
Net Stock Activity ·$2M·$79.5K$32M·
Financing Cash Flow $25M$2M$20M$-681.6K$30M$871.6K
Taxes Paid $6.8K$5.7K$4.5K$5.0K$800$2.0K
Free Cash Flow $-19M$-20M·$-11M$-8M·
Levered FCF ···$-11M$-8M·
Profitability 8
Metric Trend 202520242023202220212020
Gross Margin ···63.4%68.6%·
Operating Margin -767.0%-1091.8%·-961.7%-706.7%·
Net Margin -812.3%-1155.0%·-944.6%-639.0%·
Pretax Margin -812.2%-1154.4%·-944.1%-638.6%·
EBITDA Margin -767.0%-1091.8%·-961.7%-706.7%·
ROA -112.3%-93.6%·-50.1%-41.7%·
ROE -505.0%-454.8%·-68.5%-27.4%·
ROIC -299.7%-772.2%·-75.4%-31.5%·
Liquidity & Solvency 4
Metric Trend 202520242023202220212020
Current Ratio 4.50.9·9.215.1·
Quick Ratio 2.70.5·8.514.7·
Debt / Equity ···0.00.0·
Interest Coverage ···-861.6-433.6·
Efficiency 3
Metric Trend 202520242023202220212020
Asset Turnover 0.10.1·0.10.1·
Inventory Turnover 0.20.3·1.42.2·
Receivables Turnover 4.25.5·14.911.2·
Per Share 5
Metric Trend 202520242023202220212020
Book Value / Share $0.10$0.10·$1.28$2.23·
Revenue / Share $0.06$0.07·$0.10$0.18·
Cash Flow / Share $-0.47$-0.87·$-0.91$-1.18·
Cash / Share $0.16$0.15·$1.09$2.10·
EPS (TTM) $-0.47$-0.85$-0.93$-0.96$-1.12·
Growth Rates 3
Metric Trend 202520242023202220212020
Revenue YoY 40.8%52.0%-11.1%2.2%13.7%·
Revenue CAGR 3Y 23.9%11.4%1.1%···
Revenue CAGR 5Y 17.2%·····
Valuation (TTM) 14
Metric Trend 202520242023202220212020
Revenue TTM $2M$2M$1M$1M$1M·
Net Income TTM $-19M$-19M$-14M$-11M$-8M·
Market Cap $34M$26M·$11M$46M·
Enterprise Value ···$-2M$21M·
P/E -1.2-1.3-1.0-0.9-3.5·
P/S 15.015.8·8.939.0·
P/B 5.811.1·0.71.7·
P / Tangible Book 6.011.51.20.71.7·
P / Cash Flow -1.8-1.3·-1.0-5.8·
P / FCF -1.8-1.3·-1.0-5.6·
EV / EBITDA ···0.2-2.6·
EV / FCF ···0.2-2.6·
EV / Revenue ···-1.818.2·
Earnings Yield -81.6%-77.3%-95.4%-106.7%-28.7%·

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $2M $2M $1M $1M $1M
Gross Margin % · · · 63.4% 68.6%
Operating Margin % -767.0% -1091.8% · -961.7% -706.7%
Net Income $-19M $-19M $-14M $-11M $-8M
Diluted EPS $-0.47 $-0.85 $-0.93 $-0.96 $-1.12

Institutional owners (13F) 4 filers · $824K total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 4
Value held $824K
New positions 0
Exited positions 33
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
0 33 0 1 ·

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.

Institution Value Shares % of tracked 13F Type
VANGUARD GROUP INC $815,360 1,415,555 98.91% Shares
Pandora Wealth, Inc. $8,643 15,000 1.05% Shares
IFP Advisors, Inc $306 1,000 0.04% Shares
CX Institutional $2 750 0.00% Shares

Activists & 5%+ owners 2 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Nantahala Capital Partners Limited Partnership, Nantahala Capital Management, LLC, Wilmot B. Harkey, Daniel Mack Aug. 17, 2026 9.99% Initial filing Passive investment SEC
PharmaCyte Biotech, Inc. Nov. 22, 2023 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 20 insiders · 4 officers · 7 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Daniel Scott Currie Chief Operating Officer June 2, 2025 I 86,275 0 0 $0
Kelley Stinson Nicholas Chief Commercial Officer June 23, 2025 A · 0 0 $0
Christine E Thomas Chief Reg & Clinical Officer Jan. 28, 2025 A · 0 0 $0
Richard D. Spector Chief Commercial Officer Feb. 12, 2024 A · 0 0 $0
Joshua Silverman Director June 25, 2025 A · 0 0 $0
Anne Morrissey Director June 21, 2023 A · 0 0 $0
Wendy Perrow Director June 21, 2023 A · 0 0 $0
Keith J Kendall Director June 14, 2023 A · 0 0 $0
John Q Adams JR Director June 8, 2022 A 239,938 0 0 $0
John Dyett Director June 8, 2022 A 114,709 0 0 $0
William Benson Witte Director Dec. 15, 2021 J 12,191 0 0 $0
Jeffrey Gerald Mifek · Aug. 7, 2026 A 3,125 1 0 $10,000
John Charles Canning · Aug. 7, 2026 A 4,375 1 0 $14,000
Jeremy Alexander Sipos · Aug. 7, 2026 A 3,125 1 0 $10,000
Kathy Lee-Sepsick · Aug. 7, 2026 A 15,625 1 0 $50,000
Dov Elefant · Aug. 7, 2026 A 15,625 1 0 $50,000
Kenneth D. Eichenbaum · June 24, 2026 A · 0 0 $0
Alistair Milnes · June 24, 2026 A · 0 0 $0
Charles Larsen · June 24, 2026 A 56 0 0 $0
Edward R Uzialko · June 24, 2026 A 30,175 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 2 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS 0.00% 27,936 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 34,296 SH Aug. 19, 2026 Daily

FEMY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 9 analysts BUY
Median target $10.00 +387.8%
2 22.2% Strong Buy
6 66.7% Buy
1 11.1% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

3 analysts · 2026-10-02

Mean target $14.33 +599.2%

← Below all targets Current price $2.05
Low$10.00 Mean$14.33 High$23.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
FEMY $34M -1.2 40.8% -812.3% -505.0% ·
HSCS · · · · · ·
ICU · · · · · ·
MODD $25M -0.4 · · -260.0% ·
SINT $15M -0.6 -64.7% -1018.1% -299.7% 45.3%
CTSO · -4.9 4.1% · · ·
IRIX $20M -4.5 8.2% -8.4% -80.8% 36.5%
ABT $250.18B 33.7 5.7% 14.7% 13.1% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 14, 2026